NeuroSense to Present at American Society for Experimental Neurotherapeutics on March 3

  NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Dr. Shiran Zimri, the Company's Head of Scientific Programs, will deliver a presentation titled "Breaking the Paradigm – PrimeC as a Novel Approach to ALS Therapy" at the American Society for Experimental Neurotherapeutics (ASENT) 2022 Annual Meeting on Thursday, March 3, 2022. NeuroSense, together with Amylyx Pharmaceuticals, and the National Institute of Neuroscience in Tokyo, will co-lead a session titled "Not a One-Trick Pony: Repurposing Established Drugs for New Neurological Indications" during which Dr. Zimri will present.

NeuroSense's lead drug candidate PrimeC is a novel formulation consisting of specific doses of two FDA-approved drugs designed to work synergistically to treat amyotrophic lateral sclerosis (ALS), an incurable neurodegenerative disease that causes complete paralysis and ultimately death within 2 to 5 years from diagnosis.

"Our proprietary combination therapy approach using two well-established drugs to treat a disease as complex as ALS not only breaks the current paradigm of focusing on one target, it also potentially enables a faster path to market," Dr. Zimri commented. "With a well-established safety profile, the combination therapy's efficacy is focused on three targets: regulating microRNA synthesis, modulating iron accumulation, and attenuating neuroinflammation, and has achieved meaningful outcomes in clinical and preclinical studies to date."

PrimeC successfully met its primary endpoints in a Phase 2a trial including safety, reduced functional and respiratory deterioration, and significant changes in ALS-related biomarkers. NeuroSense expects to commence a Phase 2b ALS study in H1 2022, with a Phase 3 study slated for H2 2023.

https://finance.yahoo.com/news/neurosense-therapeutics-present-american-society-141500747.html